Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
Alloy Therapeutics and Takeda have announced a strategic collaboration and license agreement to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). The technology, developed through Takeda's T-CiRA joint research program with Kyoto University, aims to create 'off-the-shelf' cell therapies with enhanced potency and lower manufacturing costs compared to autologous cell therapy. Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Alloy will establish a Japanese subsidiary at Shonan Health Innovation Park to support these efforts.
Alloy Therapeutics e Takeda hanno annunciato una collaborazione strategica e un accordo di licenza per sviluppare la piattaforma di cellule CAR-T (iCAR-T) e la piattaforma di cellule CAR-NK (iCAR-NK) derivata da cellule staminali pluripotenti indotte (iPSC) di Takeda. La tecnologia, sviluppata attraverso il programma di ricerca congiunto T-CiRA di Takeda con l'Università di Kyoto, mira a creare terapie cellulari 'pronte all'uso' con una potenza potenziata e costi di produzione inferiori rispetto alla terapia cellulare autologa. Ai sensi dell'accordo, Alloy ottiene diritti co-esclusivi per commercializzare i prodotti iCAR-T e iCAR-NK per indicazioni oncologiche. Alloy istituirà una filiale in Giappone presso il Shonan Health Innovation Park per supportare questi sforzi.
Alloy Therapeutics y Takeda han anunciado una colaboración estratégica y un acuerdo de licencia para desarrollar la plataforma de células CAR-T (iCAR-T) y la plataforma de células CAR-NK (iCAR-NK) derivadas de células madre pluripotentes inducidas (iPSC) propiedad de Takeda. La tecnología, desarrollada a través del programa de investigación conjunta T-CiRA de Takeda con la Universidad de Kioto, tiene como objetivo crear terapias celulares 'listas para usar' con mayor potencia y costos de fabricación más bajos en comparación con la terapia celular autóloga. Según el acuerdo, Alloy obtiene derechos co-exclusivos para comercializar productos iCAR-T e iCAR-NK para indicaciones oncológicas. Alloy establecerá una filial en Japón en el Shonan Health Innovation Park para apoyar estos esfuerzos.
Alloy Therapeutics와 Takeda는 Takeda의 자산인 유도 다능성 줄기세포(iPSC) 유래 CAR-T 세포 플랫폼(iCAR-T) 및 iPSC 유래 CAR-NK 플랫폼(iCAR-NK)을 개발하기 위한 전략적 협력 및 라이선스 계약을 발표했습니다. 이 기술은 다케다와 교토대학의 T-CiRA 공동 연구 프로그램을 통해 개발되었으며, 자가 세포 치료에 비해 향상된 효능과 낮은 제조 비용을 지닌 '상용화 가능한' 세포 치료법을 만드는 것을 목표로 하고 있습니다. 이 계약에 따라, Alloy는 종양학적 적응증에 대한 iCAR-T 및 iCAR-NK 제품 상용화에 대한 공동 독점권을 얻게 됩니다. Alloy는 이러한 노력을 지원하기 위해 Shonan Health Innovation Park에 일본 지사를 설립할 것입니다.
Alloy Therapeutics et Takeda ont annoncé une collaboration stratégique et un accord de licence pour développer la plateforme de cellules CAR-T (iCAR-T) et la plateforme de cellules CAR-NK (iCAR-NK) dérivées de cellules souches pluripotentes induites (iPSC) de Takeda. La technologie, développée dans le cadre du programme de recherche conjoint T-CiRA de Takeda avec l'Université de Kyoto, a pour but de créer des thérapies cellulaires 'prêtes à l'emploi' avec une puissance accrue et des coûts de fabrication réduits par rapport à la thérapie cellulaire autologue. Selon l'accord, Alloy obtient des droits co-exclusifs pour commercialiser les produits iCAR-T et iCAR-NK pour des indications oncologiques. Alloy établira une filiale au Japon au Shonan Health Innovation Park pour soutenir ces efforts.
Alloy Therapeutics und Takeda haben eine strategische Zusammenarbeit sowie eine Lizenzvereinbarung bekannt gegeben, um Takedas eigene CAR-T-Zellplattform (iCAR-T) und die iPSC-abgeleitete CAR-NK-Plattform (iCAR-NK) zu entwickeln. Die Technologie, die durch Takedas gemeinsames Forschungsprogramm T-CiRA mit der Universität Kyoto entwickelt wurde, zielt darauf ab, 'fertige' Zelltherapien mit erhöhter Wirksamkeit und geringeren Herstellungskosten im Vergleich zur autologen Zelltherapie zu schaffen. Im Rahmen der Vereinbarung erhält Alloy das co-exklusive Recht, iCAR-T- und iCAR-NK-Produkte für onkologische Indikationen zu vermarkten. Alloy wird eine Tochtergesellschaft in Japan im Shonan Health Innovation Park gründen, um diese Bemühungen zu unterstützen.
- Development of potential 'off-the-shelf' cell therapies with enhanced potency
- Expected lower manufacturing costs compared to autologous cell therapy
- Co-exclusive commercialization rights for oncology indications
- None.
Insights
This strategic collaboration represents a significant advancement in the cell therapy landscape. The iCAR-T and iCAR-NK platforms could revolutionize cancer treatment by offering "off-the-shelf" solutions that address major limitations of current CAR-T therapies. The key advantages include potential cost reduction in manufacturing and improved accessibility compared to traditional autologous approaches.
The deal structure, granting Alloy co-exclusive commercialization rights, creates substantial value potential. The technology's foundation from Kyoto University's CiRA, combined with Takeda's development expertise and Alloy's ecosystem approach, forms a powerful combination for advancing these platforms. The establishment of Alloy's Japanese subsidiary further demonstrates long-term commitment to this collaboration.
While financial terms weren't disclosed, this partnership could significantly impact Takeda's oncology portfolio and market position in the rapidly growing cell therapy sector. The technology's potential for both solid and hematological malignancies expands the addressable market substantially.
The cell therapy market is projected to grow substantially, with significant demand for off-the-shelf solutions that can overcome the limitations of current autologous CAR-T therapies. This collaboration positions Takeda strategically in this high-growth segment, particularly important given the
The partnership model, leveraging Alloy's ecosystem approach, could accelerate commercialization timelines and expand market reach through potential sublicensing opportunities. The technology's potential for both solid tumors and blood cancers significantly expands the addressable market, though competition in the allogeneic cell therapy space is intensifying.
iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA) at
“iCAR-T is one of our flagship projects graduating from T-CiRA, our decade-long joint research program between Takeda and CiRA. This agreement between Takeda and Alloy aims to advance iCAR-T from discovery to clinical development,” said Yasushi Kajii, Head of R&D Japan Region at Takeda. “We are impressed with Alloy’s corporate culture of valuing platform technologies, flexibility in collaboration, patient-centric mindset, and company creation abilities, all of which were key elements to our decision to work with Alloy. We look forward to seeing iCAR-T and iCAR-NK blossom as the technology advances to its next phase.”
Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Alloy will leverage synergies across its unique business model to further advance the iCAR-T/NK platform while enabling broader access to the technology for biotech and pharma partners to develop therapies for cancers including solid tumors. Future clinical validation and platform enhancements will further strengthen the platform.
“We are honored and excited to be chosen by Takeda to collaborate in fulfilling the promise of iPSC,” said Errik Anderson, Founder, Chairman & CEO of Alloy. “This is another instance of how Alloy’s flexible approach allows us to enable the global scientific community with cutting edge technologies designed for rapid, successful drug development. We believe a robust engagement with the ecosystem will play a critical role in unlocking the vast potential of iPSC and enabling the next generation of cancer therapeutics.”
To support these efforts, Alloy is establishing a Japanese subsidiary at Shonan Health Innovation Park in Kanagawa Prefecture, to be led by Victor Stone (Yoshihide Ishii) as the Head of Alloy Cell Therapies and Alloy Therapeutics Japan.
* Please click here for more information on iCAR-T, an important part of this collaboration.
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120266952/en/
Media Contacts
Email: Victor Stone (Yoshihide Ishii) celltherapies@alloytx.com
Source: Alloy Therapeutics Inc.
FAQ
What is the purpose of Alloy Therapeutics and Takeda's (TAK) collaboration agreement?
What are the key benefits of Takeda's (TAK) iCAR-T technology?
What rights does Alloy Therapeutics receive in the agreement with Takeda (TAK)?
